Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer.
about
Regulation of ERBB3/HER3 signaling in cancerCIViC databaseClinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer.Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.Cross-species analysis of genetically engineered mouse models of MAPK-driven colorectal cancer identifies hallmarks of the human disease.Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes.Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.Requirement for BUB1B/BUBR1 in tumor progression of lung adenocarcinomaQuantitative Phosphoproteomics Analysis of ERBB3/ERBB4 Signaling.Tumor-Targeted Synergistic Blockade of MAPK and PI3K from a Layer-by-Layer Nanoparticle.Neuregulin-activated ERBB4 induces the SREBP-2 cholesterol biosynthetic pathway and increases low-density lipoprotein uptakeA rare population of CD24(+)ITGB4(+)Notch(hi) cells drives tumor propagation in NSCLC and requires Notch3 for self-renewalIntegrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance.Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung.Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3.Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.Translational value of mouse models in oncology drug development.Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapyMicroRNA-193a-3p and -5p suppress the metastasis of human non-small-cell lung cancer by downregulating the ERBB4/PIK3R3/mTOR/S6K2 signaling pathway.Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study).Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.Activating ERBB4 mutations in non-small cell lung cancer.HGF and NRG1 protein expression are not poor prognostic markers in surgically resected lung adenocarcinoma.A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer.Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes.Antibody-mediated stabilization of NRG1 induces behavioral and electrophysiological alterations in adult mice.
P2860
Q27024334-F1402E2B-3B61-4176-A9CA-6D4A133F6D5DQ27612411-6DF23177-73E8-4789-9BEB-D614090985ACQ27853182-3B02121D-86D8-45D8-9739-BD1D8C61279FQ33434648-B04107F7-F942-4C1E-9168-3B49AA051FFCQ33601653-39E2F7D7-69AF-4B39-B9A0-D6223BAA8C70Q33677196-6D6A5470-8F0E-4B7A-9342-94374A50EC1CQ34762165-6201EC58-0710-4445-B0B9-53AD68CB5270Q35412202-DA38279C-6C9C-4464-BA31-2FE293A5578FQ35591891-4774467F-7AF2-4DF1-A6C2-43F16B0944CDQ35888647-A67D6771-7C60-4980-866A-7C3B4049C065Q36219160-2CD8A95A-8887-415F-9776-BE0817A0C253Q36337964-89C1F8B3-4248-4BC0-9F8A-B98D026AAE48Q37582286-66D6F4C3-A5C8-4ACA-9E46-37598466E879Q38385463-ECA61CDF-16CD-436D-B47C-5FA27A091D96Q38514601-DF64F067-C3D2-4EBE-B869-802B6A61FFADQ38623361-BCB65749-D505-4ACD-ACD2-53020F840165Q38795629-96FA8180-5586-46CA-9002-1EDB162EEA82Q38878056-4388DE5E-CB76-46C4-A4D6-ECF22E6B37A9Q38945259-5032C8C9-95C9-4F6A-A971-3C86A1E589E2Q39029964-F94977F2-133C-44B3-B415-AD6334250476Q39187965-CD0890E4-AA50-4C5C-B243-3400C1CE02BEQ39886940-26AF4180-D3A8-4C6C-BD94-36615DFBB46AQ40862193-482D576E-78E5-4A28-B23D-41314414A3B2Q40867329-2BBD2265-62D1-4C32-A3EC-50A18768D840Q47158524-B7BD3454-8666-4259-85B0-EB9CAE2E98EFQ53078543-5FDF84AE-43CA-4936-A908-2221EEF3F43EQ54967456-FEEDD199-5CC3-476F-9776-53381A7DEC49
P2860
Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer.
description
2013 nî lūn-bûn
@nan
2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Blocking NRG1 and other ligand ...... of non-small cell lung cancer.
@ast
Blocking NRG1 and other ligand ...... of non-small cell lung cancer.
@en
Blocking NRG1 and other ligand ...... of non-small cell lung cancer.
@nl
type
label
Blocking NRG1 and other ligand ...... of non-small cell lung cancer.
@ast
Blocking NRG1 and other ligand ...... of non-small cell lung cancer.
@en
Blocking NRG1 and other ligand ...... of non-small cell lung cancer.
@nl
prefLabel
Blocking NRG1 and other ligand ...... of non-small cell lung cancer.
@ast
Blocking NRG1 and other ligand ...... of non-small cell lung cancer.
@en
Blocking NRG1 and other ligand ...... of non-small cell lung cancer.
@nl
P2093
P2860
P3181
P1476
Blocking NRG1 and other ligand ...... of non-small cell lung cancer.
@en
P2093
Cecile C de la Cruz
Cecilia Chiu
David Goldenberg
E Alejandro Sweet-Cordero
Erica L Jackson
Gabriele Schaefer
Ganapati V Hegde
Janet Tien
Leslie Roth
P2860
P304
P3181
P356
10.1126/SCITRANSLMED.3004438
P407
P577
2013-02-06T00:00:00Z